RAFAEL
LOPEZ CASTRO
Investigador en el periodo 2023-2023
Institute Catalá Oncología
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Institute Catalá Oncología (8)
2024
-
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Lung Cancer, Vol. 190
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789
2023
-
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study
Melanoma research, Vol. 33, Núm. 5, pp. 388-397
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
-
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
Journal of Clinical Oncology, Vol. 41, Núm. 28, pp. 4478-4485
-
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128
-
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775